Targeted inflammation of the glioblastoma microenvironment as a novel treatment approach
Glioblastoma (GB) is the most lethal form of primary brain tumours, with a median survival of 14.6 months and 15 000 new diagnoses each year in Europe and the US. Current therapies are inefficient due to the genetic heterogeneity of GB and the presence of an immunosuppressive tumour microenvironment (TME). The EU-funded GlioTarget project aims to exploit an innate immunity checkpoint to simultaneously target cancer cells and their TME. Adenosine deaminase acting on RNA 1 (ADAR1) is a central component of the RNA sensing pathway and has recently emerged as a promising immuno-oncology target with evidence that ADAR1 loss represents a specific vulnerability of cancer cells. The project will evaluate the therapeutic potential of ADAR1 inhibition alone and in combination with standard therapy and TME-targeted immunotherapies.
Fields of science
Call for proposal
See other projects for this call